Hyderabad, December 08, 2021: Gland Pharma Limited, a generic injectable focused pharmaceutical company, received a tentative approval from the United States Food and Drug Administration (US FDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials. 

Gland Pharma believes that we are amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity. 

Gland Pharma will launch the product with its marketing partner on receipt of final approval. 

About Gland Pharma Limited (BSE: 543245, NSE: GLAND)

Gland Pharma was established in 1978 in Hyderabad, has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectablefocused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions and also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: www.glandpharma.com 

Contacts: 

Sampath Kumar Pallerlamudi                                                  Sumanta Bajpayee 

Company Secretary and Compliance Officer                          Vice President – Finance & Investor Relations 

investors@glandpharma.com                                                 sumanta.bajpayee@glandpharma.com 

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Gland Pharma Limited, its directors and any of the affiliates or employee is under no obligation to, and expressly assume any obligation to update any particular forward-looking statement contained in this release.